Compare Repligen Corporation Common Stock (RGEN) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Financial Select Sector SPDR Fund — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Financial Select Sector SPDR Fund trades at $54.56 (market cap $52.24B). The key difference: Financial Select Sector SPDR Fund is far larger — about 4.7× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Financial Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| RGEN | XLF | |
|---|---|---|
Market Cap | $11.14B | $52.24B |
Volume | 1,259,263 | 44,490,388 |
Sector | Health | — |
52-Week High | $194.57 | $58.55 |
52-Week Low | $102.87 | $47.80 |
Typical Hold Time | 0 Days | 104 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
XLF trades at $54.82, down 0.42% amid mixed technical signals with a bullish moving average trend but neutral oscillators. The ETF faces sector headwinds as financial stocks lag the broader market despite rising bank profits. Recent Federal Reserve stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
The financial sector ETF shows potential for benefiting from rising interest rates, though regulatory uncertainty and market underperformance relative to the S&P 500 present near-term risks. Institutional rotation into financials in Q2 2026 suggests confidence in the sector's rate sensitivity advantages over technology stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
